Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

The FDA has designed five different types of labels, each presenting the same information but with different specifications based on the size of the packaging.

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...

As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabetes ...

Nearly 70% of adults in Indiana are classified as overweight or obese, contributing to a broader health crisis in the United ...

Treating the growing problem of childhood obesity calls for exploring new approaches and treatments through well-designed ...

In Connecticut, where Medicaid has clamped down on covering GLP-1 medications for obesity, people are looking ... be registered or might be known to the FDA,” she’ll explain.

Jay Olson, an analyst from Oppenheimer, maintained the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated price target ...